Hemangio Journal

A pilot study of the oral drug OXC-101 was presented at the American Association for Cancer Research (AACR) Annual Meeting in April. The...

Canine hemangiosarcoma cells take up boron through LAT1, making them vulnerable to neutron irradiation.

Published on: May 17, 2026

Organoids and xenografts reveal PLAAT3 as a key driver of invasion

Published on: April 4, 2026

Liver involvement remains the strongest negative prognostic indicator, but pulmonary and muscular metastases showed no significant impact on survival.

Published on: February 25, 2026

Hemangiosarcoma cells use lactate to activate genes that let them synthesize asparagine from glutamine.

Published on: February 16, 2026

This study provides the first controlled evidence that trained dogs can detect a distinct odor signature in the blood serum of dogs with hemangiosarcoma

Published on: December 28, 2025

Circulating microRNA panel could diagnose canine splenic HSA with 80% sensitivity.

Published on: December 7, 2025

This research analyzed data from the Golden Retriever Lifetime Study. Its rigorous design confirms the negative findings are due to data limitations, not a flawed methodology.

Published on: November 2, 2025

The finding opens a new avenue for research by identifying a previously overlooked pathway in canine cancer.

Published on: October 22, 2025

Data from 12 dogs showed stable cardiac troponin levels and a reduction in adverse events across treatment.

Published on: October 19, 2025

A single dose of an oncolytic virus, combined with standard care, led to a survival of over seven years for a dog with an aggressive bone hemangiosarcoma diagnosis

Published on: October 2, 2025

The study evaluated a new therapeutic approach combining standard chemotherapy with a conjugate vaccine technology called “iBoost”

Published on: September 25, 2025